Clinical Research Directory

Inclusion Criteria: * Patient is a consenting female age 40-75 years * Patient is scheduled for routine screening DBT * Patient is asymptomatic for breast disease * Patient had heterogeneously dense or extremely dense breasts on most recent prior mammography examination (Breast Imaging Reporting and Data System \[BI-RADS\] c or d) within 24 months of enrollment * Patient is able to participate fully in all aspects of the study (completing study visits and study data collection) * Patient understands and signs the study informed consent * Patient anticipates being able to return one year after study enrollment to complete the second round of screening Exclusion Criteria: * Patient is currently pregnant or plans to become pregnant during the course of the study * Patient is currently lactating * Patient has had a prior MBI * Patient has had a prior whole breast ultrasound (WBUS) for screening, with either a hand-held ultrasound probe or automated system, within 12 months prior to study enrollment * Patient has had a prior breast MRI * Patient has had a prior contrast-enhanced mammogram (contrast enhanced spectral mammography \[CESM\] or contrast-enhanced digital mammography \[CEDM\]) * Patient is concurrently participating in any other breast imaging research studies that involve undergoing additional breast imaging tests beyond routine screening with mammography, including but not limited to contrast-enhanced mammography, WBUS, MBI, or contrast-enhanced breast MRI * Patient has had a breast biopsy within 3 months prior to study enrollment * Patient has had breast surgery within 12 months prior to study enrollment * Patient is currently undergoing treatment for breast cancer or planning surgery for a high-risk breast lesion (atypical ductal hyperplasia \[ADH\], atypical lobular hyperplasia \[ALH\], lobular carcinoma in situ \[LCIS\], papilloma, radial scar) * Patient is currently taking a chemoprevention agent for breast cancer risk reduction or osteoporosis prevention (tamoxifen, raloxifene, anastrazole, letrozole, exemestane) * Patient has a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence